endpts.com Open in urlscan Pro
13.32.27.85  Public Scan

Form analysis
1 forms found in the DOM

https://endpts.com/

<form action="https://endpts.com/">
  <input type="text" name="s" placeholder="Search">
  <button class="epn_ux_button epn_white epn_search_submit_button"></button>
</form>

Text Content

 * Channels
   * All News
   * In Focus
   * Special
   * AI
   * Bioregnum
   * Biotech Voices
   * Cell/Gene Tx
   * China
   * Coronavirus
   * Deals
   * Diagnostics
   * Discovery
   * FDA+
   * Financing
   * Health Tech
   * Law
   * Letters to the Editor
   * Manufacturing
   * Marketing
   * Opinion
   * Outsourcing
   * Peer Review
   * People
   * Pharma
   * R&D
   * Startups
   * Weekly
 * Webinars
 * Biopharma Jobs
 * More
   * Work at Endpoints
   * Letter to Editors
   * IPO Tracker
   * Webinars
   * Events
   * Sponsored Posts
   * Advertise
   * Privacy Policy
   * Endpoints Merch
   * About Us
   * Help


 * SIGN UP
 * LOG IN




TOP STORIES


OBE­SI­TY AND DI­A­BETES BIOTECH CAR­MOT THER­A­PEU­TICS FILES FOR IPO

9 hours ago
Financing
Startups



MER­CK COUGH DRUG FAILS TO WIN AD­COMM’S BACK­ING AS FDA RAIS­ES EF­FI­CA­CY
QUES­TIONS

11 hours ago
R&D


PFIZ­ER, ASTEL­LAS CLINCH EX­PAND­ED AP­PROVAL FOR XTAN­DI IN EAR­LI­ER LINE OF
PROSTATE CAN­CER

12 hours ago
R&D
Pharma


Q&A WITH JU­DITH NG-CASHIN, CRO NOVOTECH'S CHIEF MED­ICAL OF­FI­CER, ON 2023 AND
BE­YOND

12 hours ago
People


LATEST


AB­B­VIE AD­VIS­ES FRUS­TRAT­ED PSO­RI­A­SIS PA­TIENTS TO GET ‘RE­AL CLEAR’ IN
NEW AWARE­NESS CAM­PAIGN

14 hours ago
Pharma
Marketing


BIDEN TAPS VAN­DER­BILT’S KIM­RYN RATH­MELL TO SUC­CEED BERTAG­NOL­LI AS THE
NI­H'S CAN­CER CHIEF

14 hours ago
People
Pharma


MER­CK NOTCH­ES 38TH AP­PROVAL FOR KEYTRU­DA, SEV­ENTH IN­DI­CA­TION FOR
GAS­TROIN­TESTI­NAL CAN­CER

15 hours ago
Pharma
FDA+


ASTEL­LAS DE­TAILS PO­TEN­TIAL REA­SON BE­HIND DEATHS IN RARE DIS­EASE GENE
THER­A­PY TRI­AL

16 hours ago
R&D
Cell/Gene Tx


CD­MOS IN­VES­TI­GATE HOW TO SUP­PORT GLP-1 MAN­U­FAC­TUR­ING, PHAR­MA
CON­SID­ERS SUP­PLY CHAIN DI­VER­SI­TY: #JEF­FERIES23

16 hours ago
Manufacturing


DANA­HER/AB­CAM DEAL SET TO CLOSE NEXT MONTH; CERENO'S LOAN; MARCH BIO­SCIENCES
TO AD­VANCE ITS CAR-T IN­TO PHII

16 hours ago
News Briefing
see latest stream
People


FDA'S JANET WOOD­COCK TO RE­TIRE IN EAR­LY 2024

Yesterday


HEARD AT #JEF­FERIES23: AL­NY­LAM, BI­CY­CLE, IN­TEL­LIA, NOUS­COM, RAKUTEN
MED­ICAL EX­ECS FORE­CAST 2024

Yesterday


THREE MONTHS AF­TER BIG RE­OR­GA­NI­ZA­TION, AN­TI­BODY MAK­ER ATRE­CA IS BACK
WITH AN­OTH­ER ROUND OF LAY­OFFS

2 days ago
Financing


BIOTECH’S IPO OUT­LOOK FOR THE REST OF THE YEAR SOURS IN WAKE OF WAR, BROAD­ER
IN­DUS­TRY STRUG­GLES

Yesterday


SCOOP: RAKUTEN MED­ICAL TAR­GETS YEAR-END CLOSE FOR $100M+ SE­RIES E TO FUND
PHO­TOIM­MUNOTHER­A­PY PIPELINE: #JEF­FERIES23

Yesterday


SCOOP: CELL­PROTHERA EYES $30M ROUND FOR PHI­II TRI­AL OF CELL THER­A­PY FOR
HEART AT­TACKS: #JEF­FERIES23

2 days ago
Startups


Q32 BIO TO TAKE HO­MOL­O­GY MED­I­CINES’ NAS­DAQ SPOT TO FUND PHII TRI­ALS IN
AU­TOIM­MUNE, IN­FLAM­MA­TO­RY CON­DI­TIONS

Yesterday


PRI­MA­RY CARE START­UP FOR­WARD RAIS­ES $100M TO GROW NA­TION­AL­LY WITH
SELF-SER­VICE ‘CARE­PODS’

2 days ago


NMD PHAR­MA SE­CURES €75M FROM IN­SID­ERS FOR THREE PHII TRI­ALS IN
NEU­RO­MUS­CU­LAR DIS­OR­DERS

2 days ago
Deals


AM­GEN LINES UP NEW AI BIOTECH PART­NER IN POSTERA TO DE­VEL­OP SMALL MOL­E­CULE
MED­I­CINES

Yesterday


ASTEL­LAS BAGS PROSTATE CAN­CER DRUG IN $175M BUY­OUT AS XTAN­DI AP­PROACH­ES
PATENT CLIFF

Yesterday


IN­VESTORS OR­BIMED AND FORE­SITE SAY THEY'RE LOOK­ING AT TAK­ING KIN­NATE
PRI­VATE, FOL­LOW­ING PIPELINE AND STAFF CUTS

2 days ago



IN FOCUSSEE ALL


FUL­LY SYN­THET­IC GENOME NEARS COM­PLE­TION IN A STEP TO­WARD UN­RAV­EL­ING
GE­NET­IC MYS­TER­IES

Last week
R&D
Discovery


MR­NA’S NEXT TRICK? RE­PRO­GRAM­MING OFF-THE-SHELF CELL THER­A­PIES FOR CAN­CER
AND AU­TOIM­MUNE DIS­EASES

Last week
Cell/Gene Tx


RA­DIO­PHAR­MA CD­MOS NAV­I­GATE SUP­PLY CHAIN, RAW MA­TE­R­I­AL CHAL­LENGES AS
DE­MAND GOES NU­CLEAR

3 weeks ago
Manufacturing


AF­TER THE AP­PLAUSE: NEW EF­FI­CA­CY EX­PEC­TA­TIONS IN UROTHE­LIAL CAN­CER
AF­TER PAD­CEV-KEYTRU­DA DA­TA RE­VEAL

3 weeks ago
R&D
Pharma


ENDPOINTS STANDOUTS


A CON­VER­SA­TION WITH NO­BEL PRIZE WIN­NER KATAL­IN KARIKÓ ON RE­JEC­TION,
FI­NAL­LY BE­ING REC­OG­NIZED AND HER MR­NA WORK

Last month
People


AF­TER YEARS OF HYPE, THE FIRST AI-DE­SIGNED DRUGS FALL SHORT IN THE CLIN­IC

5 weeks ago
AI
In Focus


HOW NO­VO NORDISK’S RY­BEL­SUS WENT FROM PAN­DEM­IC WASHOUT TO BLOCK­BUSTER, AND
WHAT’S NEXT FOR ORAL WEIGHT LOSS

4 weeks ago
Pharma
Marketing


MOST DE­TAILED HU­MAN BRAIN MAP YET IS ‘LAY­ING THE FOUN­DA­TION FOR FIND­ING
FU­TURE CURES’

Last month
R&D
In Focus


PEER REVIEW SEE ALL

Nov
17


DE­SIGN THER­A­PEU­TICS HINTS AT ‘STRATE­GIC RE­ALIGN­MENT,’ RE­PLACES CEO;
KARYOPHARM CO-FOUNDER LEADS AT­P'S NEREID

Nov
10


CEN­TU­RY THER­A­PEU­TICS NABS BRIS­TOL MY­ERS ALUM AS CEO; EN­HER­TU STAR
DAI­ICHI SANKYO MAKES CHANGES IN EU­ROPE

Nov
3


CNS BIOTECH RAP­PORT SNAGS A CFO VET­ER­AN FROM KARUNA; BRIS­TOL MY­ERS’ NEW CEO
TO CHAIR THE BOARD NEXT YEAR

Oct
27


FLAG­SHIP'S MON­TAI HEALTH HIRES FIRST CMO; FI­NANCE LEADER TO RE­TIRE AT J&J
PART­NER XEN­COR

Oct
20


CO-FOUND­ED BY DAVID BAK­ER, VILYA RINGS IN A PER­MA­NENT CEO; AL­LO­GENE NAMES
ER­IC SCHMIDT'S CFO SUC­CES­SOR


PHARMA CHANNEL FEED

20 hours ago


AS­TRAZENECA LANDS FDA AP­PROVAL FOR AKT IN­HIBITOR IN BIO­MARK­ER-DE­FINED
BREAST CAN­CER SUB­SET

As­traZeneca has scored an FDA ap­proval for its AKT in­hibitor capi­vasert­ib,
adding a new tar­get­ed ther­a­py to its treat­ment of­fer­ings in breast
can­cer.

READ MORE


SLEW OF HOUSE DE­MOC­RATS URGE FDA, HHS TO PRE­SERVE AC­CESS TO MISO­PROS­TOL,
METHOTREX­ATE

Yesterday
FDA+


'WELL UN­DER­WAY': FDA CALLS FOR FASTER CON­FIR­MA­TO­RY TRI­ALS FOR
AC­CEL­ER­AT­ED AP­PROVALS

Yesterday
FDA+
latest in Pharma


FDA HANDS DOWN AP­PROVAL FOR BRIS­TOL MY­ER­S' LUNG CAN­CER DRUG FROM TURN­ING
POINT BUY­OUT

Yesterday
FDA+


NO­VO NORDISK LAUNCH­ES HEAD-TO-HEAD TRI­AL WITH ELI LIL­LY AS WEIGHT LOSS
RI­VAL­RY HEATS UP

2 days ago


OZEM­PIC SHORT­AGES HAVE EU­RO­PEAN COUN­TRIES EX­PLOR­ING BANS ON USE OF
POP­U­LAR DRUG FOR WEIGHT LOSS

2 days ago
Manufacturing


CORMEDIX WINS US AP­PROVAL VIA RARELY-USED PATH­WAY FOR DRUG TO RE­DUCE
BLOOD­STREAM IN­FEC­TIONS

2 days ago
FDA+


A MARK CUBAN COPY? CIGNA’S EX­PRESS SCRIPTS TO OF­FER WHAT IT CALLS AN­OTH­ER
COST-PLUS PRIC­ING MOD­EL

2 days ago
Health Tech
see latest stories


MARKETING CHANNEL FEED

Yesterday


MU­SIC AGENCY CRE­ATES PAR­O­DY ‘BRAVU­RA’ DRUG AD TO AM­PLI­FY ITS KNACK FOR
PHAR­MA MAR­KET­ING SCORES

The new video ad for Bravu­ra seems to have it all — a re­as­sur­ing voiceover,
tired and con­cerned pa­tients, an over­ly long list of po­ten­tial side
ef­fects and mu­sic crescen­dos and ...

READ MORE


KLICK HEALTH AGENCY ADDS AI TEAMS TO AC­CEL­ER­ATE PHAR­MA AND HEALTH­CARE
MAR­KET­ING PROJECTS

Yesterday
AI
Pharma


PHAR­MAS AND PHYSI­CIANS VAL­UE MED­ICAL AF­FAIRS AND MSLS, BUT HAVE DIF­FER­ENT
CON­TENT PRI­OR­I­TIES, SUR­VEY SAYS

2 days ago
Pharma
latest in Marketing


SANOFI HANDS OUT COM­MU­NI­TY HEALTH EQ­UI­TY GRANTS IN ON­GO­ING EF­FORT TO
BUILD TRUST WITH MAR­GIN­AL­IZED GROUPS

2 days ago
Pharma


ELI LIL­LY WINS PRE­LIM­I­NARY IN­JUNC­TION IN MOUN­JARO CASE IN DRUG­MAK­ER­S'
ON­GO­ING BAT­TLE WITH COM­POUND­ING PHAR­MA­CIES, WELL­NESS SPAS

2 days ago
Pharma
Law


HOW VI­RAL TIK­TOK TRENDS ARE CATCH­ING ON IN PHAR­MA MAR­KET­ING

3 days ago


NO­VAR­TIS ADDS TO MUL­TI­PLE SCLE­RO­SIS 'LOVE STO­RY' CAM­PAIGN WITH MORE
PA­TIENT PER­SPEC­TIVES

3 days ago
Pharma


MAR­KET­INGRX ROUNDUP: VI­A­TRIS DE­BUTS NEW CAM­PAIGN IN TIMES SQUARE;
AS­TRAZENECA RE­NEWS NAT­UR­AL GAS DEAL

3 days ago
Pharma
see latest stories


FDA+ CHANNEL FEED

Yesterday


IN A WORLD FIRST, VER­TEX, CRISPR WIN UK AP­PROVAL FOR CRISPR-EDIT­ED THER­A­PY
TO TREAT SICK­LE CELL DIS­EASE, BE­TA-THA­LASSEMIA

Ver­tex and CRISPR Ther­a­peu­tics have won the first-ever ap­proval for a
ther­a­py cre­at­ed with CRISPR gene edit­ing, as the UK drug reg­u­la­tor MHRA
green­lights their treat­ment for two blood ...

READ MORE


CAN POST-MAR­KET EV­I­DENCE GEN­ER­A­TION BE STREAM­LINED? FDA-COM­MIS­SIONED
RE­PORT PRO­POS­ES SO­LU­TIONS

2 days ago
Pharma


FDA RAIS­ES CON­CERNS OVER EF­FI­CA­CY OF MER­CK­'S PO­TEN­TIAL CHRON­IC COUGH
DRUG AHEAD OF AD­COMM

2 days ago
Pharma
latest in FDA+


AMA­ZON LANDS FDA WARN­ING LET­TER OVER DIS­TRI­B­U­TION OF SEV­EN UN­AP­PROVED
EYE DROPS

3 days ago


NEW NIH CHIEF STRESS­ES FO­CUS ON OBE­SI­TY, CLIN­I­CAL TRI­AL CHAL­LENGES

3 days ago
Pharma


FDA TOUTS NEW AU­THOR­I­TY AS ODAC HOSTS AD­COMM TO RE­VIEW DE­LAYED
CON­FIR­MA­TO­RY TRI­ALS FOR AC­CEL­ER­AT­ED AP­PROVALS

3 days ago


JAPAN CON­SID­ERS AD­JUST­ING CLIN­I­CAL TRI­AL RE­QUIRE­MENTS TO RE­MOVE THE
NEED FOR LO­CAL STUD­IES — RE­PORT

4 days ago
Pharma


FDA EX­PLAINS WHY IT DE­NIED ABOUT 60% OF NON-ON­COL­O­GY BREAK­THROUGH
THER­A­PY RE­QUESTS FROM 2017 TO 2019

4 days ago
Pharma
see latest stories


MANUFACTURING CHANNEL FEED

16 hours ago


LIL­LY IN­VESTS $2.5B IN NEW GER­MAN SITE TO BOOST TIRZEPATIDE SUP­PLY, $100M
FOR LO­CAL BIOTECHS

Eli Lil­ly is set to build a new $2.5 bil­lion fa­cil­i­ty in Ger­many to
in­crease man­u­fac­tur­ing ca­pac­i­ty for its block­buster di­a­betes and
obe­si­ty drugs, and the phar­ma gi­ant al­so ...

READ MORE


AS­TRAZENECA SUB­SIDIARY TO SELL ITS BAN­GA­LORE SITE, TO HUNT FOR EX­TER­NAL
MAN­U­FAC­TUR­ER 

20 hours ago


SAN­DOZ OPENS TWO NEW FA­CIL­I­TIES; GATES FOUN­DA­TION FUNDS NEE­DLE-FREE
VAC­CINES; NO­VAR­TIS EX­PANDS JAPAN­ESE SITE

Yesterday
latest in Manufacturing


IS THE WORST OVER? CATAL­ENT TOUTS GLP-1 AND GENE THER­A­PY BUSI­NESS AS IT
STICKS TO FI­NAN­CIAL GUID­ANCE

2 days ago


EX­CLU­SIVE: NTX RAIS­ES $47.5M SE­RIES B TO COM­MER­CIAL­IZE PRO­TEIN, MR­NA
MAN­U­FAC­TUR­ING PLAT­FORMS 

2 days ago
Financing


AJI­NOMO­TO TO BUY GENE THER­A­PY CD­MO FORGE BI­O­LOG­ICS IN $620M ALL-CASH
DEAL

4 days ago
Deals


THER­MO FISH­ER PLANS TO LAY OFF 97 EM­PLOY­EES, CLOSE FA­CIL­I­TY IN AL­ABA­MA

Last week
People


NO­VO IN­VESTS $6B+ TO EX­PAND MAN­U­FAC­TUR­ING FA­CIL­I­TIES AS DE­MAND FOR
WE­GOVY SKY­ROCK­ETS

Last week
Pharma
Cell/Gene Tx
see latest stories

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas




LATEST

 * All News
 * Special
 * In Focus
   


CHANNELS

 * AI
 * Bioregnum
 * Biotech Voices
 * Cell/Gene Tx
 * China
 * Coronavirus
 * Deals
 * Diagnostics
 * Discovery
 * FDA+
 * Financing
 * Health Tech
 * Law
 * Letters to the Editor
 * Manufacturing
 * Marketing
 * Opinion
 * Outsourcing
 * Peer Review
 * People
 * Pharma
 * R&D
 * Startups
 * Weekly


MORE

 * Work at Endpoints
 * Letter to Editors
 * IPO Tracker
 * Events
 * Webinars
 * Sponsored Posts
 * Advertise
 * Endpoints Merch
 * About Us
 * Help


WORK IN BIOTECH

 * Endpoints Careers

© Endpoints News 2023

 * Help
 * Advertise
 * Privacy Policy
 * Business Model




LOG IN TO YOUR ACCOUNT


EMAIL




PASSWORD


Change my password Get a magic email link
LOG IN


REQUEST MAGIC LINK

If you're already an Endpoints subscriber, enter your email below for a magic
link that lets you log in quickly without using a password. Please note the
magic link is one-time use only and expires after 24 hours.


EMAIL


BACK
REQUEST


RESET PASSWORD

We'll e-mail you a link to set a new password. Please note this link is one-time
use only and is valid for only 24 hours.


EMAIL


BACK
RESET

SIGN UP FOR FREE TO READ A LIMITED NUMBER OF ARTICLES EACH MONTH.

ABOUT YOU







NEWSLETTER INTERESTS

PICK WHAT NEWSLETTERS GET DELIVERED TO YOUR INBOX EACH WEEK.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET



EARLY EDITION Daily at 7:15 AM ET



ENDPOINTS PHARMA Daily at 2 PM ET



BREAKING NEWS ALERTS 2-3 times a week



ENDPOINTS MARKETING RX Tue at 2 PM ET



ENDPOINTS FDA+ Wed at 2 PM ET



ENDPOINTS MANUFACTURING Thu at 2 PM ET



ENDPOINTS WEEKLY Sat at 6 AM ET



Healthcare

ENDPOINTS HEALTH TECH Coming soon


INSTANT SIGN UP

Want unlimited access? Sign up for a premium subscription plan.